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Polysaccharopeptide enhances the anticancer activity of doxorubicin and 
etoposide on human breast cancer cells ZR-75-30 
Abstract 
In search of natural bioactive microbial compounds with adjuvant properties, we have previously showed 
that the polysaccharopeptide (PSP), isolated from Chinese medicinal mushroom Coriolus versicolor, was 
able to enhance the cytotoxicity of certain S-phase targeted-drugs on human leukemic HL-60 cells via 
some cell-cycle and apoptotic-dependent pathways. The present study aimed to investigate whether the 
synergism of mechanisms of PSP with certain chemotherapeutic drugs also applies to human breast 
cancer. PSP treatment enhanced the cytotoxicity of doxorubicin (Doxo), etoposide (VP-16) but not 
cytarabine (Ara-C). Bivariate bromodeoxyuridine (BrdUrd)/DNA flow cytometry analysis estimated a 
longer DNA synthesis time (Ts) for the PSP treated cancerous cells suggesting that PSP enhanced the 
apoptotic effect of Doxo and VP-16 via creating an S-phase trap in the human breast cancer cell line 
ZR-75-30. The participation of PSP in the apoptotic machinery of the chemotherapeutic agents was 
further supported by a reduced ratio of protein expression of Bcl-xL/Bax of the cancer cells. This study 
provides further insight into the synergistic mechanisms of PSP and supports the hypothesis that the 
anticancer potentials of PSP is not limited to leukemia but may also be used as an adjuvant therapy for 
breast cancers. 
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Abstract. In search of natural bioactive microbial compounds
with adjuvant properties, we have previously showed that the
polysaccharopeptide (PSP), isolated from Chinese medicinal
mushroom Coriolus versicolor, was able to enhance the cyto-
toxicity of certain S-phase targeted-drugs on human leukemic
HL-60 cells via some cell-cycle and apoptotic-dependent
pathways. The present study aimed to investigate whether
the synergism of mechanisms of PSP with certain chemo-
therapeutic drugs also applies to human breast cancer. PSP
treatment enhanced the cytotoxicity of doxorubicin (Doxo),
etoposide (VP-16) but not cytarabine (Ara-C). Bivariate
bromodeoxyuridine (BrdUrd)/DNA flow cytometry analysis
estimated a longer DNA synthesis time (Ts) for the PSP
treated cancerous cells suggesting that PSP enhanced the
apoptotic effect of Doxo and VP-16 via creating an S-phase
trap in the human breast cancer cell line ZR-75-30. The
participation of PSP in the apoptotic machinery of the chemo-
therapeutic agents was further supported by a reduced ratio
of protein expression of Bcl-xL/Bax of the cancer cells. This
study provides further insight into the synergistic mechanisms
of PSP and supports the hypothesis that the anti-cancer
potentials of PSP is not limited to leukemia but may also be
used as an adjuvant therapy for breast cancers.
Introduction
Breast cancer is one of the most frequent cancers in the world
(1), and it is the commonest cancer amongst women (1,2).
The mortality of breast cancer is low (1), however, because
of its high incidence and the increasing global trend (1,3,4), it
results in medical costs worldwide estimated to be more than
US$7 billion (3). The absence of estrogen receptor (ER) is
found to be associated with higher recurrence rate (5), and
patients with an ER-negative status have a significantly
shorter median survival time (6). Hormonal therapy, one of
the treatment used to tackle breast cancer, is reported to be
completely ineffective in ER-negative breast cancers (7),
therefore rendered the high importance of chemotherapy in
ER-negative breast cancer patients. 
However, chemotherapy comes with side effects such as
alopecia (8) and leucopenia (9) because it does not differentiate
between cancerous cells and normal cells (9-15). Many efforts
have been put into the search for anti-tumor agents that can
distinguish cancerous cells from normal cells, as well as
adjuvant therapies that can enhance the cytotoxicity of the
anti-tumor drugs to cancerous cells, which give potential of
lowering chemotherapeutic drugs to reduce the side effects.
Combined chemotherapy has also been tried in the hope of
reducing the drug-induced side effects as well as increasing
the anti-tumor specificity. 
When searching for natural anticancer compounds for
combination therapy, it is essential to identify novel compounds
that are capable of potentiating the chemotherapeutic value
of the anticancer drugs but at the same time exert no
cytotoxic effect to normal cells. In this respect, the poly-
saccharopeptide (PSP), isolated from the mycelium of the
medicinal Chinese mushroom of the species Coriolus
versicolor, known as Yun Zhi, offers great potential in cancer
combined treatment therapy because of its ability to
distinguish cancerous cells from normal cells (16-20). PSP is
currently in phase II clinical trials in China, with great success
including high survival rates, improved immunological
activities, appetite and comfort for patients status (19). The
anticancer mechanisms of PSP include induction of apoptosis
in cancer cells (21-24) and enhancement of host immune
response (24-28).
The active component of Yunzhi, polysaccharopeptide
(PSP), consists of 6 types of monosaccharides, namely man-
nose, glucose, xylose, galactose, arabinose and rhamnose,
connected with a small polypeptide (17). Fig. 1 gives an
illustration of the partial structure of the polysaccharide moiety
of PSP. The polypeptide moieties of PSP are rich in aspartic
and glutamic acids (Table I) (17-19). In a recent study, we
have demonstrated that PSP was able to potentiate the
chemotherapeutic activities of certain cell cycle-specific
anticancer drugs. When combined with S-phase-specific
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chemotherapeutic drugs, we observed that PSP was effective
in potentiating the cytostatic and apoptotic effects of both
doxorubicin (Doxo) and etoposide (VP) on the human leukemic
HL-60 cells (24). In the present study, the ZR-75-30 cancer cell
line, an estrogen receptor (ER) negative human breast cancer
was chosen in order to investigate whether PSP can potentiate
the cytostatic and apoptotic effects of doxorubicin, etoposide
and cytarabine on human breast cancer.
The 5'-Bromo-2'-deoxyuridine (BrdUrd) labeling of
DNA technique with flow cytometry (29-33) was applied
to investigate the cell cycle-specific actions of PSP and its
interaction with Doxo, VP-16, and Ara-C. The present study
showed that the combined treatment of S-phase targeting
drugs with PSP also resulted in higher cytotoxicity than drugs
given alone in the ZR-75-30 cancer cells. Flow cytometry
analysis indicates that PSP enhanced the cytotoxicity of
the tested drugs by creating an S-phase trap in ZR-75-30
cells. This study provides further insight into the synergistic
mechanisms of PSP and supports the hypothesis that the anti-
cancer potentials of PSP is not limited to leukemia but may
also be used as an adjuvant therapy for breast cancers.
Materials and methods
Reagents. Cytarabine (Ara-C), doxorubicin (Doxo), dimethyl
sulfoxide (DMSO) and protease inhibitor cocktail were
purchased from Sigma. Etoposide (VP-16) was purchased
from Calbiochem. Polysaccharopeptide (PSP) was obtained
from the Winsor Health Products Ltd. in form of capsules
(340 mg/capsule). The crude powder of PSP was dissolved
in distilled water, and the water soluble fraction was then
freeze-dried. The freeze-dried powder was then dissolved
in distilled water to prepare a solution at concentration of
10 mg/ml. Stock solutions of Ara-C and Doxo were prepared in
distilled water, and VP-16 was dissolved in DMSO. Annexin V
binding assay easy to use detection kit (Apoptosis Detection
Kit) was obtained from Trevigen Inc. Monoclonal anti-human
Bcl-2, anti-human Bax, anti-human Bcl-xL and anti-human Bid
antibody were supplied from Santa-Cruz Biotechnology. 
Cell culture. ZR-75-30 cell line used in this study is an estrogen
receptor (ER)-negative human breast cancer (34) derived
from the ascite fluid of a 47-year-old post-menopausal Black
women with infiltrating duct carcinoma (35) and it was a
generous donation of Dr Mabel Young from the Department
of Physiology, the University of Hong Kong. ZR-75-30 was
routinely culture in RPMI medium supplemented with 10%
fetal bovine serum. The densities of the cells were monitored
to ensure they did not exceed 2x107 cells per 80 cm2 culture
flask. Cells were cultured at 37°C in a humidified atmosphere
with 5% CO2. The cultures were supplied with fresh complete
medium and the cell density was adjusted to 1x106 cells
per flask every three days to maintain asynchronous and
exponential growth. In all experiments, they were fed with
fresh complete medium a day before the experiment.
Cell proliferation analysis. The time (24, 48, 72 h) and dose-
dependent (0-400 μg/ml) effect of PSP on the proliferation of
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Figure 1. The partial structure of polysaccharide moiety of PSP (17).
Table I. Amino acids composition in polypeptide moiety of
PSP (17).
–––––––––––––––––––––––––––––––––––––––––––––––––
Amino acid Content (%) Amino acid Content (%)
–––––––––––––––––––––––––––––––––––––––––––––––––
Aspartic acid 4.0 Methionine 0.4
Glutamic acid 5.8 Isoleucine 2.2
Threonine 2.3 Leucine 2.4
Serine 3.2 Tyrosine 1.5
Proline 1.0 Phenylalanine 1.5
Glycine 2.6 Tryptophan 1.7
Alanine 2.6 Lysine 2.3
Cystine 0.9 Histidine 0.7
Valine 1.8 Arginine 1.8
––––––––––––––––––––––––––––––––––––––––––––––––– 
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ZR-75-30 human breast cancer cells were studied by culturing
the cells with or without (RPMI only) PSP as described
above. Preparation of PSP has been described elsewhere by
us (16,24). After trypsinization, 100 μl cancer cell aliquots
and 100 μl of Trypan-blue solution was added to a 1.5 ml
microcentrifuge tube which was then mixed thoroughly and
incubated at room temperature for 5 min. Total number of
cells in four 1 mm2 corners of hemacytometer was counted,
and the average number of cells per unit volume of medium
was calculated.
Study 1: the influence of cell cycle kinetics of PSP on ZR-75-30
human breast cancer cells measured by bivariate BrdUrd/
DNA flow cytometry. Previous report with human leukemic
cells (16,24) indicated that one of the anticancer properties of
PSP involves S-phase cell cycle arrest. This study sought to
investigate the influence of cell cycle kinetics of PSP on the
ZR-75-30 human breast cancer cells by using the bromo-
deoxyuridine labeling and bivariate BrdUrd/DNA technique
analysis by flow cytometry. 
To investigate the effect of PSP on tumor growth and
cell cycle distribution (G0/G1, S and G2/M), ZR-75-30 cell
suspensions at 2x106 cells were exposed with or without PSP
at concentrations ranging between 5 and 400 μg/ml. The
cells were incubated for 24, 48 or 72 h, harvested and
examined by various analyses. The fixed samples were stored
at -20˚C for further analysis by DNA/PI flow cytometry.
To study the effect of PSP on the cell cycle kinetics
[labeling index (LI), relative movement (RM), DNA synthesis
time (Ts) and G0/G1 cells returned or labeled divided cells
(Lud)], ZR-75-30 cells with 48-h pretreatment of PSP (50 μg/
ml) or without (control) were pulsed with 10 μM of BrdUrd
for 20 min. After pulse-labeling with BrdUrd, cells were
washed with warm cell culture medium, divided and subjected
to culture incubation for 1 or 6 h. At the end of incubation,
cells were harvested and fixed with ice-cold 75% ethanol.
The fixed samples were stored at -20˚C for further analysis
by flow cytometry.
The bivariate BrdUrd/DNA technique analysis by flow
cytometry is based on simultaneous measurement of the total
incorporation or the rate of incorporation of the thymidine
analog, BrdUrd, into newly synthesized DNA (30-32). The
uptake of BrdUrd in each cell can be detected by immuno-
cytochemical staining techniques that involve binding the
BrdUrd to fluorescein isothiocyanate (FITC) labeled anti-
BrdUrd monoclonal antibodies (green fluorescence). The
quantity of BrdUrd (green fluorescence) and DNA (red
fluorescence labels by propidium iodide) can be simultaneously
measured in the same cells. This analysis estimates the relative
number of cells actually involved in cell division (labeling
index) and may also provide estimates of the rate of DNA
synthesis.
By repeating the bivariate BrdUrd/DNA analysis of labeled
cells at several time-points, it is possible to determine the rate
of progression of BrdUrd-labeled cells as they accumulate
more DNA. The movement of the BrdUrd-labeled cells
(cycling cells) between the G0/G1 and G2/M cell cycle phases
can be used to calculate the ‘relative movement’ (RM). By
using two different relative movements (RM(t)) extracted
from the different BrdUrd pulse-labeling time, the DNA
synthesis time (Ts) of the cancer cells can be calculated
according to the methods previously described (29-33):
RM(t) = (Flud(t) - FG0/G1)/(FG2/M - FG0/G1)
Ts = 0.55(t)/(RM(t) - RM(0))
where Flud(t), FG0/G1 and FG2/M are the mean PI fluorescence
(DNA content) of the BrdUrd labelled undivided cells of the
G0/G1 and G2/M population at time (t) (hour) after BrdUrd
pulsing. RM(0) and RM(t) are the relative movement values
at time 0 and t (hour) after BrdUrd pulsing respectively.
RM(0) is estimated to be 0.55.
Immunocytochemical staining for BrdUrd/DNA flow cytometry
analysis. Staining of cancer cells for bivariate analysis of
BrdUrd was performed as previouly described by us (29,33,36)
and by other investigators (30) with some modifications.
Cells were harvested into 15 ml centrifuge tubes. All samples
were washed twice with 10 ml PBS and centrifuged at 400 g
for 5 min. Supernatant was removed and cell pellets were
re-suspended in 100 μl ice-cooled PBS. Cells were fixed by
adding ice-cold EtOH (70% w/v in Milli-Q water) dropwisely
into the tubes while the cells were being vortexed. The fixed
samples were stored at -20˚C for further analysis.
The fixed samples were washed twice each with 10 ml PBS
and the DNA of cells were partially denatured by incubation
with 2 M HCl (0.5 ml) for 30 min. After denaturation, cells
were washed three times with 10 ml PBS containing 0.05%
Tween-20 (PBS-T). The cells were incubated with 100 μl of
anti-BrdUrd antibody (1:100 dilution) and incubated at room
temperature for 1 h. After incubation, cells were washed
twice with PBS-T and subsequently incubated with 100 μl of
FITC-conjugated anti-mouse IgG antibody (1:40 dilution) to
label the primary antibodies in dark at room temperature for
1 h. Following the incubation, cells were washed twice with
PBS and the DNA of cells was stained with propidium iodide
(PI) staining solution (50 μg/ml PI, 10 μg/ml RNase, 0.01 M
Tris-base and 10 mM NaCl in milli-Q water) for 30 min at
room temperature. The stained cells were analyzed by Coulter's
Epics Elite ESP flow cytometer at 525 nm and 620 nm band
pass filters.
Study 2: The combined anticancer effect of PSP with doxo-
rubicin (Doxo), etoposide (VP-16) and cytarabine (Ara-C).
Based on the cell cycle kinetic study of study 1, the testing
hypothesis of this study was that by creating an S-phase trap,
PSP can enhance the cell killing effect of chemotherapeutic
agents namely doxorubicin, etoposide and cytarabine with
S-phase interference activity on the ZR-75-30 cells. The
ZR-75-30 cells were treated with PSP (50 μg/ml) or without
(non PSP treated) for 48 h before adding the individual tested
drugs. Both PSP pretreated and non-PSP treated cells were
exposed to 5 μM of Ara-C, VP-16 or Doxo for further 18 h.
The total treatment time of PSP was 66 h. Cells were harvested
for annexin V/PI flow cytometry analysis for cell death and
Western blot analysis of the Bcl-2 family genes.
Quantification of cell death by annexin V/PI flow cytometry.
The theoretical background of this detection method has been
previously described (37). Annexin V binding assay was
INTERNATIONAL JOURNAL OF ONCOLOGY  32:  689-699,  2008 691
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performed by using an apoptosis detection kit. Cells (2x105)
after incubation with or without PSP and drugs were harvested
and centrifuged at 400 x g for 5 min to remove culture medium.
Cell pellets were washed with 3 ml phosphate buffer saline
(PBS) and re-suspended in 500 μl binding buffer. After
centrifugation and removal of binding buffer, 100 μl of
annexin V incubation reagent (10 μl 10X binding buffer,
10 μl propidium iodide (PI), 1 μl annexin V conjugate and
79 μl milli-Q water) was added to each sample. The samples
were incubated for 15 min in the dark at room temperature.
The cell suspension was then diluted with 400 μl binding
buffer and was analyzed by flow cytometer. 
Western blot analysis of the expression of Bcl-2 family proteins.
Cells were harvested and washed twice with ice-cold PBS
(45 ml) followed by centrifugation at 400 x g for 5 min. Cell
pellet was re-suspended in lysis buffer (5x106 cells/100 μl
lysis buffer) with HEPES (25 mM; pH 7.5), NaCl (150 mM),
EDTANa2 (1 mM), DTT (1 mM), Triton X-100 (1%) and
protease inhibitor cocktail. The suspension was then frozen
and thawed three times by cold methanol at -80˚C. The iced
suspension was sonicated to melting point. Cell suspension
was then placed in ice for further 30 min and then centrifuged.
After centrifugation at 14,000 x g for 30 min at 4˚C, the
suspension was collected and stored at -80˚C. Protein quantity
was determined by Bradford assay. Protein extracts were
mixed with equal volume of 2X sample buffer (0.125 M
Tris-HCl, 4% SDS, 20% v/v glycerol, 0.2 M DTT, 0.02%
bromophenol blue, pH 6.8) and the mixture was boiled in
water for 3 min.
Equal amounts of total protein (20 μg) were subjected to
12.5% SDS-PAGE followed by Western blotting onto a PVDF
membrane. Membranes were incubated with anti-human Bcl-2,
anti-human Bax, anti-human Bid and anti-human Bcl-xL
antibodies, and detected with the matching species-specific
secondary HRP-conjugated antibodies. Proteins were detected
using the ECL system (GE Healthcare) and the band intensity
was measured by Quantity One software (Bio-Rad).
Statistical analysis. All data are presented as mean ± standard
error of the mean (SEM). Statistical significance was calculated
using two-tail Student's t-test for two groups and One-way
ANOVA analysis for multi-group comparison. p<0.05 was
considered as statistically significant.
Results
The anti-proliferation effect of PSP on ZR-75-30 cells. Treat-
ment with PSP delayed the proliferation of ZR-75-30 cells in
a dose-dependent (Fig. 2a) and time-dependent (Fig. 2b)
manner. At 50 μg/ml of PSP, proliferation was decreased by
36.8% after 48-h treatment. Measured by annexin V/PI flow
cytometry, at 72-h treatment, PSP induced significant cell
death (p<0.001) by 23.9% (Fig. 3).
Effect of PSP on the human breast cancer ZR-75-30 cell
cycle distribution. The cell cycle distribution of ZR-75-30
cells, measured by DNA/PI flow cytometry, shows that PSP
was capable of inhibiting the cell proliferation via alteration
of cell cycle. At 48 h, PSP induced cell arrest in the S-phase
by 34% (p<0.01) with a corresponding decrease of cell
proportions in G0/G1 and G2/M phases (Fig. 4) compared to
control.
Effect of PSP on labeling index (LI), relative movement
(RM), and DNA synthesis time (Ts) of human breast cancer
ZR-75-30 cells. Fig. 5 presents the contour plot of the
bivariate BrdUrd/DNA flow cytometry analysis from the 1-
and 6-h BrdUrd pulse labeling of the PSP treated and control
(non-PSP treated) cells. The S-phase BrdUrd labeled cell
population of the 1-h BrdUrd contour plot is used to estimate
the labeling index (LI) of the cancer cells as described (29-
33). The 6-h contour plots show that the BrdUrd labeled cells
have moved through the S-phase in the cell cycle and some
had not yet divided (Lud) whereas others had done so. The
newly divided daughter cells population detected by anti-
BrdUrd-monoclonal antibodies of the G0/G1 phase was used to
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Figure 2. The time and dose effect of PSP on the proliferation of human breast cancer ZR-75-30 cell proliferation. (a) dose-dependent effect; (b) time-dependent
effect.
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calculate the labeled divided cells (Ld). The relative
movement calculated from the 6-h BrdUrd/DNA flow
cytometry (RM 6) (Fig. 5) was used to calculate the DNA
synthesis time (Ts) of the cancer cells. Table II summarized
the effect of PSP on LI, RM, Ld and Ts of the cancer cells
with and without PSP treatment. The data show that PSP
arrested cells in S-phase and resulted in significant higher
calculated labeling index. It is noteworthy that PSP
treatment significantly (p<0.01) retarded the relative
movement (1 and 6 h) of the cancer cells. PSP arrested cells
in S-phase resulted in a hyper-prolongation from 12.51 to
18.31 h for the DNA synthesis of the cancer cells. The DNA
synthesis time of ZR-75-30 cells was extended by 46.4%
(p<0.01). Calculation of the labeled divided cells also
dropped from 8.58 to 3.67% suggesting some interference
might have occurred at the G2/M phase.
The effect of anti-tumor drugs alone and PSP pretreatment with
anti-tumor drug on cell death and cell viability in ZR-75-30.
To investigate the interaction of PSP with the chemotherapeutic
drugs, cell death was performed with annexin V/PI flow cyto-
metry. Fig. 6 indicates that comparing to the cancer cells
administered only the corresponding individual chemo-
therapeutic agent treatment, the apoptotic effect of Ara-C,
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Figure 3. The effect of PSP on cell death of ZR-75-30 cells. The cells without (control) and with PSP (50 μg/ml) treatment for 48 and 72 h were subjected to
annexin V/PI flow cytometry analysis. The dot plots representing data on viable cells (R3) and dead cells (R1, R2, R4) at 48 and 72 h, respectively. Values are
mean ± SEM (n=4). ***p<0.001 compared with control.
Figure 4. The effect of PSP on the cell cycle distribution. Cancer cells without (control) or with 50 μg/ml PSP incubation for 48 h were fixed with PI for
staining of DNA. The cell population (%) distribution among the G0/G1, S and G2/M phase was analyzed by DNA/PI flow cytometry. Values are mean ± SEM
(n=4). **p<0.01 compared with control.
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Doxo and VP-16 on the ZR-75-30 cells was further enhanced
in cells with PSP pretreatment by 18.8%, 55.4% (p<0.001)
and 161% (p<0.001), respectively. The viability of these cells
dropped by 8.8, 33.2 (p<0.001) and 48.8% (p<0.001) with
Ara-C, Doxo, and VP-16, respectively.
Effect of PSP with and without Ara-C, Doxo and VP-16 on
apoptotic protein expression in human breast cancer ZR-75-30
cells. Western blot analysis of protein level presented in Fig. 7
shows that among the apoptotic genes measured, Bax gene
expression was the strongest in the ZR-75-30 cells. Fig. 8
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Figure 5. The effect of PSP on the labeling index and labeled divided cells: measured by bivariate BrdUrd/DNA flow cytometry. Contour plots of bivariate
BrdUrd/DNA flow cytometry distribution of the breast cancer cells without or with PSP (50 μg/ml) treatment for 48 h were generated from the 1 and 6 h
BrdUrd pulse labels, respectively. The S-phase cells situated in between 2N (G0/G1) and 4N (G2/M) labeled positively with BrdUrd, and this population of cells
were used to estimate the labeling index (LI, %). The 6-h BrdUrd/DNA contour plot shows that some S-phase cells incorporated BrdUrd and had progressed
through the G2/M phase; further divided and appeared in G0/G1 as daughter cells or labeled divided cells (Ld). Some cells remained undivided and expressed as
labeled undivided cells (Lud). Values are mean ± SEM (n=4). **p<0.01 compared with control.
Table II. The effect of PSP on labeling index, labeled divided cells, relative movement and DNA synthesis time of the ZR-75-30
cells.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Time (h) LI (%) Ld (%) RM Ts
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Control 1 31.9±0.4 0.66±0.01
PSP 1 42.8±1.3a 0.59±0.01a
Control 6 8.58±0.52 0.82±0.01 12.51±0.56
PSP 6 3.67±0.24a 0.73±0.01a 18.31±0.63a
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
All data are expressed as mean ± SEM (n=4). ap<0.01 vs control; PSP (50 μg/ml). LI, labeling index, extracted from the 1-h bivariate
BrdUrd/DNA flow cytometric contour plot; Ld, labeled divided, extracted from the 6-h bivariate BrdUrd/DNA flow cytometric contour plot;
RM, relative movement; extracted from both 1- and 6-h bivariate BrdUrd/DNA flow cytometric contour plot; Ts, DNA synthesis time;
Ts = 0.55(t)/(RM(t) - RM(0)), where Flud(t), FG0/G1 and FG2/M are the mean PI fluorescence (DNA content) of the BrdUrd labelled undivided
cells of the G0/G1 and G2/M population at time (t) (hour) after BrdUrd pulsing; RM(0) and RM(t) are the relative movement values at time 0 and
t (hour) after BrdUrd pulsing, respectively. RM(0) is estimated to be 0.55.
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
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summarizes the relative expression of the Western plotted
proteins and shows that comparing to the control, PSP
treatment alone increased the pro-apoptotic Bax expression
by 107% while that of Bid was reduced by 45%. Expression
of the anti-apoptotic protein Bcl-xL was reduced by 51%.
When comparing the chemotherapeutic agents, they
produced similar effects, i.e. increasing Bax expression and
decreasing Bcl-xL and Bid expression. Doxo treatment
increased Bax expression by 39% and reduced Bcl-xL and
Bid expression by 39 and 62%, respectively. Ara-C treatment
increased expression of Bax by 209% and decreased Bcl-xL
by 45%. Expression of Bid was decreased by 70% as well.
VP-16 treatment increased Bax expression by 220%, while
Bcl-xL and Bid expression were decreased by 52 and 90%,
respectively.
Compared with the corresponding non-PSP treated groups,
combination treatment of PSP with Doxo increased the expres-
sion of Bax by 92.1% and slightly decreased the expression
of Bcl-xL by 24.6%. The change of bid expression in Doxo
with PSP is insignificant. In the combination treatment of
INTERNATIONAL JOURNAL OF ONCOLOGY  32:  689-699,  2008 695
Figure 6. The combined effect of PSP with Ara-C, Doxo or VP-16 on the cell death of ZR-75-30 cells. The cancer cells either without (non-PSP) or with PSP
(50 μg/ml) pretreatment for 48 h all received 5 μM of Ara-C, Doxo or VP-16 for 18 h. The total treatment time of PSP was 66 h. The population of dead cells
was determined by Annexin V/PI flow cytometry. The R3 represents viable cells and the R1, R4 and R2 areas represent dead cells (PI+, Annexin+ or both).
Values are mean ± SEM (n=4). ***p<0.001 compared with non-PSP treated.
Figure 7. The combined effect of PSP with Ara-C, Doxo, VP-16 on expression of the cell death proteins Bcl-xL Bid and Bax. The cancer cells either with or
without PSP pretreatment for 48 h all received 5 μM of Ara-C, Doxo or VP-16 for 18 h. The total treatment time of PSP was 66 h.
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PSP with VP-16, the change in Bax expression is insignificant
while Bid expression was doubled. Bcl-xL expression was
decreased by 35.4%. Combined treatment of PSP with
Ara-C, to our surprise, reduced the expression of Bax by
9.4%, while Bcl-xL expression was decreased by 21.8%.
Change in Bid expression is insignificant.
Fig. 8d shows that all treatment groups decreased the
Bcl-xL/Bax ratio. PSP alone decreased the ratio by 76.45%
while Ara-C, Doxo and VP-16 given alone decreased the
ratio by 82.4, 56.0 and 84.9%, respectively. Compared with
the corresponding non-PSP treated groups, PSP further
decreased the Bcl-xL/Bax ratio induced by Doxo by 60.6%,
Ara-C by 13.0% and VP-16 by 37.5%.
Discussion
Breast cancer is one of the most frequent cancers in the world
(1), and it is the commonest cancer amongst women (1,2).
Because of the advancement in breast cancer therapy, the
mortality is low compared to other types of cancers (1).
Therapies used for breast cancer include hormonal therapy
(7,38), chemotherapy (39), a combination of both (40), and
surgical removal of the malignant tissue. Surgical removal
results in psychological issues such as low self-esteem (41),
which is highly undesirable. Hormonal therapy is reported
to be ineffective in ER-negative breast cancers (7), therefore
chemotherapy in ER-negative breast cancers is very
important. Many chemotherapeutic agents, however, are also
toxic to normal cells (10-15), leading to side effects like loss
of hair (8), impaired immune function (9), etc. which limited
their efficacy.
Combined chemotherapy offers hope and the success
depends on the interaction between the candidate drugs
(42-44). Several drugs with similar cell cycle-dependent
properties can be scheduled properly to produce a maximal
killing effect in combined chemotherapy. In this regard, PSP
is likely a potential candidate as an adjuvant therapy for
cancer treatment via its cell cycle interaction with the cytotoxic
action of several S-phase targeting chemotherapeutic agents.
The superior property of PSP over other chemotherapeutic
drugs can be its ability to distinguish cancerous cells from
normal cells (16,18-20).
Generally speaking, a phase-specific anticancer agent will
produce a maximal cell killing effect only if it allows cycling
cells to enter the cytotoxic phase, i.e. the S-phase (42-46). In
the present study, we have demonstrated that by encouraging
the cycling cells to enter the cytotoxic S-phase, PSP potentiated
the cell killing effect of the two S-phase targeting drugs
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Figure 8. The combined effect of PSP with Ara-C, Doxo or VP-16 on the relative expression of the cell death proteins Bcl-xL Bid, Bax and Bcl-xL/Bax ratio.
The cancer cells either with or without PSP pretreatment for 48 h all received 5 μM of Ara-C, Doxo or VP-16 for 18 h. The total treatment time of PSP was
66 h. The relative expression of (a) Bax; (b) Bid; (c) Bcl-xL and (d) Bcl-xL/Bax ratio.
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Doxo and VP-16 (10,47-52) but not Ara-C on the human
breast cancer ZR-75-30 cells (Fig. 6). The flow cytometric
method used in the current study is based on simultaneous
measurements of BrdUrd incorporation into cellular DNA
(S-phase) and total cellular DNA content. This technique
potentially overcomes many of the problems associated with
the use of radioactive labels and autoradioactivity required to
measure cell kinetics. By use of a single ‘pulse’ labeling of
BrdUrd and harvesting and staining of the cancer cells for
BrdUrd and DNA at two time points, it was possible to obtain
detailed estimates of DNA synthesis time Ts. The extended
Ts (from 12 to 18 h) of the PSP-pretreated ZR-75-30 cells
indicated that DNA synthesis of the cycling cells in the
cytotoxic phase had been affected to a certain extent. With
the interference of DNA synthesis process, PSP provoked the
cell death of the ZR-75-30 cells induced by cell cycle specific
cytotoxic anticancer agents Doxo and VP-16 by 55 and
161%, respectively (Fig. 6). 
The ability of PSP to arrest the cancer cells in the DNA
synthesis S-phase (led to a higher labeling index as time of
measurement) is thus our proposed mechanism on how PSP
sensitized the human breast cancer ZR-75-30 cells to under-
go cell death induced by the two S-phase targeting drugs
Doxo and VP-16 in the present study (Fig. 6). The ‘S-phase
trap theory’ of PSP was first observed in human leukemic
HL-60 cells reported by us (16). The elevation of the DNA
enzyme topoisomerase IIα and the G1-S-phase checkpoint
cyclin, cyclin E (24) measured in the PSP-treated HL-60 cells
supported the interference of DNA synthesis as part of the
mechanistic anticancer action of PSP. 
Recent evidence indicates that PSP induces cell death of
cancer cells via well defined apoptotic program (16,22-24,47).
When combined with the anticancer agents, the annexin V/PI
flow cytometric data indicated that PSP was only able to
enhance the apoptotic induction effect of Doxo and VP-16,
but not Ara-C on the ZR-75-30 cells. Another interesting
observation drawn from this study is that Ara-C was in fact
found to be the most potent anticancer agent among the three
anti-tumor agents tested alone, while Doxo was found to be
the least effective in ZR-75-30 breast cancer. 
This is unclear as to why PSP hinders the cytotoxic effect
of Ara-C, but our data indeed reflects the importance of proper
drugs selection for cancer treatment. Such antagonistic result
from the combined treatment of Ara-C and PSP may be
caused by the removal of the ZR-75-30 cells by PSP in the
G1-S boundary, which was reported as the target phase of
Ara-C (46,48). Ara-C, as a pyrimidine analogue, exerts its
cytotoxic action essentially by incorporation into the genome
of target cells (48). Whether PSP was able to delay the
cytotoxic action of Ara-C by preventing its incorporation into
the DNA of the cancer cells DNA has yet to be determined. 
Western blot analysis of the Bcl-2 family proteins, which
are essential in modulating apoptosis (49-53), was performed
to investigate the cell death mechanism of action of PSP on
the ZR-75-30 cells at protein level. It has been shown that
some of the breast cancer cell lines do not express Bcl-2 (54),
e.g. ZR-75-1 which is a close clone of ZR-75-30. Bcl-xL has
been shown to confer multi-drug resistance in several
squamous cell carcinomas (52), as well as to delay apoptosis
in breast cancer (53). Our results showed that the expression
of Bcl-2 in ZR-75-30 is too low to be detected (Fig. 7), while
Bcl-xL was expressed, suggesting Bcl-xL may have taken the
anti-apoptotic role of Bcl-2. Bax, on the other hand, was
shown to be pro-apoptotic in various cancer cell lines (50-55),
including breast cancer (56-58), and is expressed in the
ZR-75-30 cells. Bid, another pro-apoptotic protein (59,60),
was also expressed in ZR-75-30 cells.
It is found that Bax expression (Fig. 8a) was increased to
different extents under all treatments. PSP alone increased
Bax protein level. Among the three chemotherapeutic drugs
tested, both Ara-C and VP-16 given alone caused a significant
increase in Bax expression while Doxo caused only a slight
increase. However, with PSP pretreatment, the expression of
Bax was further increased with Doxo and slightly increased
with VP-16, while that of Ara-C was decreased. The Western
blot result coincides with the cell death data analyzed by
DNA/PI flow cytometry (Fig. 6), which showed that the
synergistic effect was not observed in Ara-C enhanced the
cell death with PSP pre-treatment. On the other hand, PSP
alone and all drugs on their own decreased Bcl-xL expression
(Fig. 8c). With PSP pretreatment, the Bcl-xL expression was
further decreased to different extent. Compared with the
single drug treatment groups, the Bcl-xL/Bax ratio was
decreased in the combined treatment group (Fig. 8d). This
may explain the discordance of Bax expression with cell death
data, because it has been suggested that Bcl-xL/Bax ratio is a
more important indicator of cell death (61,62), and we have
previously reported that the apoptotic machinery induced by
PSP involves a decrease in the Bcl/Bax ratio (16). Expression
of Bid, surprisingly, was suppressed in all kinds of treatments.
The change of Bid expression in drugs alone comparing to
drugs with PSP pretreatment is insignificant, suggesting PSP
may not potentiate the cytotoxicity of Doxo, Ara-C and
VP-16 in ZR-75-30 cells via modulation of Bid expression,
which is one of the common ways to induce apoptosis (60).
In conclusion, the present study indicates that PSP can
activate the cellular apoptotic program of Doxo and VP-16
on human breast cancer cells by creation of an S-phase trap.
The data provide support for some early reports (16,20-24)
that PSP derived from Cov-1 strain promotes cancer cell
suicide through a firmly controlled program (apoptosis). Up-
regulation of pro-apoptotic Bax and down-regulation of anti-
apoptotic Bcl-xL, and therefore, a decrease in Bcl-xL/Bax
ratio was found to be associated with cell death induction
synergism of mechanisms of PSP with certain chemo-
therapeutic drugs. Activation of the cellular apoptotic
program is a current strategy for the treatment of cancers.
The present study provides the first evidence to support the
development of PSP as an adjuvant therapy in human breast
cancer because of its ability to activate the cytotoxicity of
chemotherapeutic drugs. However, the data also imply the
importance of understanding its interaction with certain
individual anticancer agents. 
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